MedTrace Logo

Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment

NCT00154713 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2005-09-12

No results posted yet for this study

Summary

The specific aims of this study are as follows:

1. Primary endpoint: to evaluate the clinical responses of vaccinated patients.
2. Secondary endpoint: to evaluate the safety of this treatment and the immune responses against CEA before and after the treatment

Conditions

Interventions

BIOLOGICAL

CEA pulsed dendritic cells

Sponsors & Collaborators

  • National Health Research Institutes, Taiwan

    collaborator OTHER

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Jacqueline Whang-Peng, M.D. · National Health Research Institutes, Taiwan

  • Hui-Ju Ch'ang, M.D. · National Health Research Institutes, Taiwan

  • Ann-Li Cheng, M.D. · National Taiwan University Hospital

  • Ko-Jiunn Liu, Ph.D. · National Health Research Institutes, Taiwan

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Completion
2005-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00154713 on ClinicalTrials.gov